Evidence map›Paper›PMID 42210649›Full record

ArticleJournal of global health2026

Resilience to HPV vaccine safety scares in seven countries.

Mallory K Ellingson, Milkie Vu, Dur-E-Nayab Waheed, Swati Saxena, Fernando Pio de la Hoz, Natalia Pasternak, Yvonne Morrissey, Sharon Hanley, Michelle Fiscus, Tsetsegsaikhan Batmunkh and 2 more

Abstract read
In one paragraph

Article in Journal of global health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mallory K EllingsonGillings School of Global Public Health, University of North Carolina, Department of Health Behavior, Chapel Hill, North Carolina, USA.
Milkie VuFeinberg School of Medicine, and Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Department of Preventive Medicine, Chicago, Illinois, USA.
Dur-E-Nayab WaheedUniversity of Antwerp, Centre for the Evaluation of Vaccination, Antwerp, Belgium.
Swati SaxenaAmerican Cancer Society, New Dehli, India.
Fernando Pio de la HozUniversidad Nacional de Colombia, Bogota, Colombia.
Natalia PasternakColumbia University, Center of Science and Society, New York City, New York, USA.
Yvonne MorrisseyHSE National Immunisation Office, Dublin, Ireland.
Sharon HanleyUniversity of Aberdeen, Institute of Applied Health Sciences, Aberdeen, Scotland.
Michelle FiscusAssociation of Immunization Managers, Rockville, Maryland, USA.
Tsetsegsaikhan BatmunkhNational Cancer Council of Mongolia, Ulaanbataar, Mongolia.
Paulo AlmeidaInstituto Questao de Ciencia, Sao Paulo, Brazil.
Noel T BrewerGillings School of Global Public Health, University of North Carolina, Department of Health Behavior, Chapel Hill, North Carolina, USA.

Funding

Cancer Control Education ProgramT32CA057726 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Melissa B Gilkey, Melissa A. Troester · 2017 to 2026
$3.7M
NCI NIH HHS T32 CA057726
6 · The paper itself

Abstract

Background: Resilience is the ability of a vaccination programme to return to high coverage after a disrupting event, such as a safety scare that undermines vaccine provision. To identify insights that can help countries achieve resilience in their vaccination programmes, we reviewed the experiences of countries that faced HPV vaccine safety scares. Methods: We developed case studies on HPV vaccine safety scares in three high-income (Denmark, Ireland, and Japan) and four middle-income countries (Brazil, Colombia, India, and Mongolia). The case studies included information on the safety scare, subsequent response, and impact on HPV vaccine uptake. Results: Reports of unfounded HPV vaccine safety concerns were amplified through traditional broadcast media coverage and perpetuated by parent groups and political leaders. After safety scares, five countries had widespread decreases in HPV vaccine coverage, one had regional drops in coverage, and two suspended introductions of the vaccine. Countries' strategies varied, but typically involved coalitions of government entities, healthcare providers, community leaders, and cancer prevention organisations. All the countries were able to increase their HPV vaccine coverage or restart vaccine introduction. Conclusions: Safety scares were often imported from other countries, gained momentum through traditional media coverage, and were abetted by political leaders, delays by some vaccination programmes, and the absence of effective crisis communication plans. To build resilient HPV vaccination programmes, leaders should respond quickly to safety scares, develop a broad coalition (providers, political and community), share credible messages that emphasise cancer prevention, and communicate across traditional and social media.

Indexed as

Immunization ProgramsPapillomavirus InfectionsPapillomavirus VaccinesBrazilColombiaFemaleHumansIndiaIrelandJapanMongoliaPapillomavirus Vaccines

Identifiers

PMID42210649
PMCPMC13221712

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.